POWERbody™ is a “booster” technology platform that combines Adagene’s SAFEbody® masking technology with cutting-edge cancer treatment modalities to deliver optimal efficacious dosages to the tumor microenvironment, or TME.
POWERbody™ applies our SAFEbody technology to powerful antibody-based modalities such as creating new bispecific T-cell engagers, antibody-drug conjugates (ADCs), or antibodies that are designed to reach beyond the therapeutic potency of traditional monospecific antibodies.
POWERbody technologies are all designed to facilitate favorable druggability, manageable CMC attributes, and reduced immunogenicity.
2021.02.01 | Exelixis and Adagene Enter into Collaboration and License Agreement to Develop Novel Masked Antibody-Drug Conjugate Therapies with Improved Safety and Efficacy Profiles
2020.06.10 | Adagene Announces Strategic Collaboration Agreement with Tanabe Research Laboratories
2019.04.24 | Adagene and ADC Therapeutics Announce SAFEbody™ License Agreement